烟雾吸入性急性肺损伤的临床研究进展

刘佩华; 路潇; 李露茜; 梁璐

doi:10.13201/j.issn.1009-5918.2023.04.010

烟雾吸入性急性肺损伤的临床研究进展

- 1.
  河北大学研究生院(河北保定，071000)
- 2.
  河北大学附属医院急诊科

详细信息

通讯作者: 梁璐，E-mail：lianglu1974@163.com

^△审校者

中图分类号: R644

收稿日期: 2022-06-29

刊出日期: 2023-04-10

Advances in clinical research on smoke inhalation-induced acute lung injury

- 1.
  Graduate School of Hebei University, Baoding, Hebei, 071000, China
- 2.
  Department of Emergency, Affiliated Hospital of Hebei University

More Information

Corresponding author: LIANG Lu, E-mail: lianglu1974@163.com

Received Date: 29 June 2022

Publish Date: 10 April 2023

摘要

摘要: 烟雾吸入性急性肺损伤是烧伤患者发病率和死亡率较高的主要原因，其病理生理机制复杂，治疗上仍以支持治疗为主，并且目前国内外尚无统一的烟雾吸入性急性肺损伤的临床治疗指南或共识，目前已有多种针对性药物为临床治疗提供了新的思路和方法。本文就近10年来烟雾吸入性急性肺损伤的病理生理机制及目前针对性药物治疗的进展作一综述。
- 烟雾吸入性急性肺损伤 /
- 病理生理 /
- 治疗
Abstract: Smoke inhalation-induced acute lung injury is the main cause of morbidity and mortality in burn patients. The pathophysiological mechanisms of this injury are complex, and supportive care remains the mainstay of treatment. Currently, there is no unified clinical treatment guideline or consensus for smoke inhalation-induced acute lung injury, both domestically and abroad. However, several targeted drugs have provided new ideas and methods for clinical treatment. This article provides a review of the pathophysiological mechanisms of smoke inhalation-induced acute lung injury over the past 10 years, as well as the current progress in targeted drug therapy.
- smoke inhalation-induced acute lung injury /
- pathophysiology /
- therapies

HTML全文

参考文献(19)

[1]	纵加强, 韩志海. 烟雾吸入性急性肺损伤药物治疗的研究进展[J]. 国际呼吸杂志, 2021, 41(6): 459-463. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXCD201104015.htm
[2]	Watso JC, Romero SA, Moralez G, et al. Adults with well-healed burn injuries have lower pulmonary function values decades after injury[J]. Physiol Rep, 2022, 10(10): e15264.
[3]	Puyana S, Ruiz S, Amador F, et al. The outcomes of inhalation injuries in lesser burns: still a deadly injury[J]. Eplasty, 2021, 21: e7.
[4]	Guo BX, Bai YC, Ma YN, et al. Preclinical and clinical studies of smoke-inhalation-induced acute lung injury : update on both pathogenesis and innovative therapy[J]. Ther Adv Respir Dis, 2019, 13: 1753466619847901.
[5]	房国祥, 尹文. 布地奈德对急性肺损伤治疗作用的临床观察[J]. 临床急诊杂志, 2017, 18(3): 198-199, 203. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC201703010.htm
[6]	Holley AD, Reade MC, Lipman J, et al. There is no fire without smoke! Pathophysiology and treatment of inhalational injury in burns: a narrative review[J]. Anaesth Intensive Care, 2020, 48(2): 114-122. doi: 10.1177/0310057X20913282
[7]	Chenoweth JA, Albertson TE, Greer MR. Carbon monoxide poisoning[J]. Crit Care Clin, 2021, 37(3): 657-672. doi: 10.1016/j.ccc.2021.03.010
[8]	Gigengack RK, Cleffken BI, Loer SA. Advances in airway management and mechanical ventilation in inhalation injury[J]. Curr Opin Anaesthesiol, 2020, 33(6): 774-780. doi: 10.1097/ACO.0000000000000929
[9]	Kennedy S, Cahill KC. Cyanide poisoning in inhalation injuries[J]. Clin Case Rep, 2020, 8(12): 3566-3567. doi: 10.1002/ccr3.3099
[10]	Galeiras R. Smoke inhalation injury: a narrative review[J]. Mediastinum, 2021, 5: 16. doi: 10.21037/med-21-7
[11]	Wang WM, Liu Y, Zhang H, et al. Preparation of inhalable quercetin-β-cyclodextrin inclusion complexes using the supercritical antisolvent process for the prevention of smoke inhalation-induced acute lung injury[J]. J CO2 Util, 2023, 69: 102414. doi: 10.1016/j.jcou.2023.102414
[12]	Zhang F, Wang ZG, Li MY, et al. Puerarin attenuates smoke inhalation injury by regulation of Th1/Th2 expression and inhibition of Th17 cells in rats[J]. Int Immunopharmacol, 2015, 28(1): 546-553. doi: 10.1016/j.intimp.2015.07.023
[13]	何梅英, 陈文婷. 乌司他丁对脓毒症急性肺损伤的保护作用研究[J]. 临床急诊杂志, 2019, 20(3): 232-234. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC201903013.htm
[14]	Phelps MK, Olson LM, Patel MAVB, et al. Nebulized heparin for adult patients with smoke inhalation injury: a review of the literature[J]. J Pharm Technol, 2020, 36(4): 130-140. doi: 10.1177/8755122520925774
[15]	Miller AC, Elamin EM, Suffredini AF. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review[J]. Crit Care Med, 2014, 42(2): 413-419. doi: 10.1097/CCM.0b013e3182a645e5
[16]	Miller AC, Rivero A, Ziad S, et al. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury[J]. J Burn Care Res, 2009, 30(2): 249-256. doi: 10.1097/BCR.0b013e318198a268
[17]	Fukuda S, Lopez E, Ihara K, et al. Superior effects of nebulized epinephrine to nebulized albuterol and phenylephrine in burn and smoke inhalation-induced acute lung injury[J]. Shock, 2020, 54(6): 774-782. doi: 10.1097/SHK.0000000000001590
[18]	Esechie A, Kiss L, Olah G, et al. Protective effect of hydrogen sulfide in a murine model of acute lung injury induced by combined burn and smoke inhalation[J]. Clin Sci(Lond), 2008, 115(3): 91-97. doi: 10.1042/CS20080021
[19]	Mercel A, Tsihlis ND, Maile R, et al. Emerging therapies for smoke inhalation injury: a review[J]. J Transl Med, 2020, 18(1): 141.